NO990433L - New compounds and compositions for the treatment of diseases associated with tryptase activity - Google Patents
New compounds and compositions for the treatment of diseases associated with tryptase activityInfo
- Publication number
- NO990433L NO990433L NO990433A NO990433A NO990433L NO 990433 L NO990433 L NO 990433L NO 990433 A NO990433 A NO 990433A NO 990433 A NO990433 A NO 990433A NO 990433 L NO990433 L NO 990433L
- Authority
- NO
- Norway
- Prior art keywords
- compositions
- treatment
- diseases associated
- new compounds
- tryptase activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
- C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
- C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D233/14—Radicals substituted by oxygen atoms
Abstract
Foreliggende oppfinnelse angår nye forbindelser som er tryptaseinhibitorer; deres farmasøytisk akseptable salter og N-oksider; deres anvendelse som terapeutiske midler, samt fremgangsmåter for deres fremstilling.The present invention relates to novel compounds which are tryptase inhibitors; their pharmaceutically acceptable salts and N-oxides; their use as therapeutic agents, as well as methods of their preparation.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2313996P | 1996-07-30 | 1996-07-30 | |
US89577297A | 1997-07-17 | 1997-07-17 | |
PCT/US1997/013422 WO1998004537A1 (en) | 1996-07-30 | 1997-07-30 | Novel compounds and compositions for treating diseases associated with tryptase activity |
Publications (2)
Publication Number | Publication Date |
---|---|
NO990433D0 NO990433D0 (en) | 1999-01-29 |
NO990433L true NO990433L (en) | 1999-03-25 |
Family
ID=26696778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO990433A NO990433L (en) | 1996-07-30 | 1999-01-29 | New compounds and compositions for the treatment of diseases associated with tryptase activity |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0934293A1 (en) |
JP (1) | JP2001509787A (en) |
KR (1) | KR20000029679A (en) |
CN (1) | CN1073103C (en) |
AU (1) | AU733621B2 (en) |
CA (1) | CA2262542A1 (en) |
CZ (1) | CZ29799A3 (en) |
EE (1) | EE9900036A (en) |
FI (1) | FI990171A (en) |
HU (1) | HUP0003267A3 (en) |
LV (1) | LV12291B (en) |
NO (1) | NO990433L (en) |
NZ (1) | NZ333713A (en) |
PL (1) | PL331465A1 (en) |
SI (1) | SI9720047A (en) |
SK (1) | SK8599A3 (en) |
WO (1) | WO1998004537A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221914B1 (en) | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
US6613769B1 (en) * | 1998-02-06 | 2003-09-02 | Max-Planck-Gesellschaft zur Föderung der Wissenschaften. e.V. | Tryptase inhibitors |
ES2233025T3 (en) * | 1998-02-06 | 2005-06-01 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | AGENT INHIBITORS OF TRIPTASE. |
IL141654A0 (en) * | 1998-09-04 | 2002-03-10 | Byk Gulden Lomberg Chem Fab | Pyranose derivatives and pharmaceutical compositions containing the same |
SI1208089T1 (en) * | 1999-08-10 | 2005-04-30 | Altana Pharma Ag | Diazocin-dione derivatives and their use as tryptase inhibitors |
EP1216236A1 (en) * | 1999-09-14 | 2002-06-26 | Byk Gulden Lomberg Chemische Fabrik GmbH | Tryptase inhibitors |
WO2001036386A1 (en) * | 1999-11-17 | 2001-05-25 | Sumitomo Pharmaceuticals Co., Ltd. | Diabetic remedy containing dipiperazine derivative |
DE19955476A1 (en) * | 1999-11-18 | 2001-05-23 | Boehringer Ingelheim Pharma | Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments |
JP2003518087A (en) | 1999-12-20 | 2003-06-03 | アルタナ ファルマ アクチエンゲゼルシャフト | Tryptase inhibitor |
CA2392121A1 (en) * | 1999-12-20 | 2001-06-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tryptase inhibitors |
SI1358182T1 (en) * | 2001-01-31 | 2005-02-28 | Altana Pharma Ag | Diazocine derivates and their use as tryptase inhibitors |
CA2438711A1 (en) | 2001-02-21 | 2002-08-29 | Altana Pharma Ag | Tryptase inhibitors |
ES2278913T3 (en) | 2001-02-21 | 2007-08-16 | Altana Pharma Ag | INHIBITING AGENTS OF TRIPTASAS. |
CA2440482A1 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
WO2002074732A2 (en) * | 2001-03-15 | 2002-09-26 | Altana Pharma Ag | Tryptase-inhibitors |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
CA2449729C (en) | 2001-06-11 | 2009-11-03 | Xenoport, Inc. | Prodrugs of gaba analogs, compositions and uses thereof |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1401809B1 (en) | 2001-06-19 | 2006-12-20 | ALTANA Pharma AG | Tryptase inhibitors |
KR101228399B1 (en) | 2004-11-04 | 2013-01-31 | 제노포트 인코포레이티드 | Gabapentin prodrug sustained release oral dosage forms |
CA2737335C (en) * | 2008-12-19 | 2013-10-01 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
TWI432188B (en) | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases |
FR3038605B1 (en) | 2015-07-06 | 2018-08-24 | Universite Amiens Picardie Jules Verne | VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE |
EP3623368A4 (en) * | 2017-05-12 | 2021-04-07 | Riken | Class a gpcr-binding compound modifier |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4845242A (en) * | 1987-04-28 | 1989-07-04 | Georgia Tech Research Corporation | Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents |
WO1994020527A1 (en) * | 1993-03-12 | 1994-09-15 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
US5525623A (en) * | 1993-03-12 | 1996-06-11 | Arris Pharmaceutical Corporation | Compositions and methods for the treatment of immunomediated inflammatory disorders |
US5656660A (en) * | 1994-06-01 | 1997-08-12 | Arris Pharmaceutical Corporation | Compositions and methods for treating mast-cell mediated conditions |
EE03525B1 (en) * | 1994-09-23 | 2001-10-15 | Arris Pharmaceutical Corporation | Compositions for the treatment of mast cell-mediated inflammatory conditions |
NZ305626A (en) * | 1995-03-24 | 2000-01-28 | Axys Pharm Inc | Reversible protease inhibitors |
TW438591B (en) * | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
-
1997
- 1997-07-30 SI SI9720047A patent/SI9720047A/en unknown
- 1997-07-30 HU HU0003267A patent/HUP0003267A3/en unknown
- 1997-07-30 CZ CZ99297A patent/CZ29799A3/en unknown
- 1997-07-30 WO PCT/US1997/013422 patent/WO1998004537A1/en not_active Application Discontinuation
- 1997-07-30 KR KR1019997000757A patent/KR20000029679A/en not_active Application Discontinuation
- 1997-07-30 SK SK85-99A patent/SK8599A3/en unknown
- 1997-07-30 EE EEP199900036A patent/EE9900036A/en unknown
- 1997-07-30 JP JP50913698A patent/JP2001509787A/en active Pending
- 1997-07-30 CN CN97196877A patent/CN1073103C/en not_active Expired - Fee Related
- 1997-07-30 CA CA002262542A patent/CA2262542A1/en not_active Abandoned
- 1997-07-30 NZ NZ333713A patent/NZ333713A/en unknown
- 1997-07-30 EP EP97937066A patent/EP0934293A1/en not_active Withdrawn
- 1997-07-30 AU AU39670/97A patent/AU733621B2/en not_active Ceased
- 1997-07-30 PL PL97331465A patent/PL331465A1/en unknown
-
1999
- 1999-01-29 NO NO990433A patent/NO990433L/en not_active Application Discontinuation
- 1999-01-29 FI FI990171A patent/FI990171A/en unknown
- 1999-02-18 LV LVP-99-27A patent/LV12291B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN1226892A (en) | 1999-08-25 |
WO1998004537A1 (en) | 1998-02-05 |
HUP0003267A3 (en) | 2002-02-28 |
SK8599A3 (en) | 2000-03-13 |
CA2262542A1 (en) | 1998-02-05 |
PL331465A1 (en) | 1999-07-19 |
EE9900036A (en) | 1999-08-16 |
CZ29799A3 (en) | 1999-06-16 |
JP2001509787A (en) | 2001-07-24 |
HUP0003267A2 (en) | 2001-06-28 |
FI990171A0 (en) | 1999-01-29 |
KR20000029679A (en) | 2000-05-25 |
NZ333713A (en) | 2000-12-22 |
NO990433D0 (en) | 1999-01-29 |
LV12291A (en) | 1999-06-20 |
EP0934293A1 (en) | 1999-08-11 |
AU733621B2 (en) | 2001-05-17 |
LV12291B (en) | 2000-04-20 |
SI9720047A (en) | 1999-08-31 |
CN1073103C (en) | 2001-10-17 |
FI990171A (en) | 1999-03-23 |
AU3967097A (en) | 1998-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO990433L (en) | New compounds and compositions for the treatment of diseases associated with tryptase activity | |
AU2003301020A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
NO20021328L (en) | Pyrazolopyrimidia as therapeutic agents | |
NO20012977D0 (en) | N-ureidoalkylpiperidines as modulators of chemokine receptor activity | |
NO20093464L (en) | New drug mixtures based on anti-cholinergically effective compounds and beta-mimetics | |
SE0202462D0 (en) | Novel use | |
DK1178958T3 (en) | N-cyanomethylamides as protease inhibitors | |
MXPA02012712A (en) | N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity. | |
NO992400L (en) | New substituted pyrazole derivatives | |
NO991732L (en) | New heterocyclylmethyl substituted pyrazole derivatives | |
NO20051263L (en) | New use of benzothiazole derivatives | |
ATE302606T1 (en) | N-UREIDOALKYLPIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | |
BR0109211A (en) | 5-ht1a Activity Compounds Useful for Treatment of External Retinal Disorders | |
NO963731L (en) | Treatment of obsessive-compulsive diseases with 5HT2 antagonists | |
NO20014529D0 (en) | Tetrahydropyran derivatives and their use as therapeutic agents | |
NO20073113L (en) | Indenyl derivatives and their use for the treatment of neurological disorders | |
DK0888271T3 (en) | Benzamidine derivatives substituted with amino acid and hydroxy acid derivatives and their use as anticoagulants | |
NO20016201L (en) | Tienopyrimidines as phosphodiesterase inhibitors | |
DE60031686D1 (en) | PYRAZINONE, COMPOSITIONS CONTAINING THESE COMPOUNDS | |
NO982863L (en) | New compounds with analgesic effect | |
DK0871446T3 (en) | Use of eliprodil in the manufacture of a medicament for the treatment of ischemic diseases of the retina or optic nerve | |
BR0317289A (en) | Method for treating movement disorders using barbituric acid derivatives | |
WO2000076500A8 (en) | Compound for use as a medicament for treatment of disorders involving bronchocontraction | |
DK0767783T3 (en) | Substituted alkyl diamine derivatives and their use as tachykinin antagonists | |
BRPI0415546A (en) | compound, pharmaceutical composition, use of a compound, and methods of treatment or prophylaxis of human diseases or conditions, and disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |